Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 12-21 |
| Number of pages | 10 |
| Journal | Hematol. Oncol. |
| Volume | 38 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 2020 |
Keywords
- lymphoma
- magnetic resonance imaging
- positron emission tomography
- whole-body imaging
- contrast medium
- fluorodeoxyglucose f 18
- gadolinium
- radiopharmaceutical agent
- rituximab
- anaplastic large cell lymphoma
- apparent diffusion coefficient
- B cell lymphoma
- cancer staging
- diffuse large B cell lymphoma
- diffusion weighted imaging
- follicular lymphoma
- gastrointestinal lymphoma
- Hodgkin disease
- human
- intermethod comparison
- mantle cell lymphoma
- peripheral T cell lymphoma
- positron emission tomography-computed tomography
- predictive value
- priority journal
- radiation exposure
- Review
- T cell lymphoma
- treatment response
- whole body MRI
- animal
- nuclear magnetic resonance imaging
- procedures
- whole body imaging
- Animals
- Humans
- Lymphoma
- Magnetic Resonance Imaging
- Neoplasm Staging
- Whole Body Imaging
Fingerprint
Dive into the research topics of 'Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art: Hematological Oncology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art : Hematological Oncology. / Albano, D.; Bruno, A.; Patti, C.; Micci, G.; Midiri, M.; Tarella, C.; Galia, M.
In: Hematol. Oncol., Vol. 38, No. 1, 2020, p. 12-21.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Whole-body magnetic resonance imaging (WB-MRI) in lymphoma: State of the art
T2 - Hematological Oncology
AU - Albano, D.
AU - Bruno, A.
AU - Patti, C.
AU - Micci, G.
AU - Midiri, M.
AU - Tarella, C.
AU - Galia, M.
N1 - Cited By :3 Export Date: 25 February 2021 CODEN: HAOND Correspondence Address: Albano, D.; Section of Radiological Sciences, Italy; email: albanodomenico@me.com Chemicals/CAS: fluorodeoxyglucose f 18, 63503-12-8; gadolinium, 7440-54-2; rituximab, 174722-31-7 References: Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012 (2012) CA Cancer J Clin, 62 (1), pp. 10-29. , https://doi.org/10.3322/caac.20138; Siegel, D.A., King, J., Tai, E., Buchanan, N., Ajani, U.A., Li, J., Cancer incidence rates and trends among children and adolescents in the United States, 2001-2009 (2014) Pediatrics, 134 (4). , https://doi.org/10.1542/peds.2013-3926; Albano, D., Patti, C., Narese, D., Mulè, A., Midiri, M., Galia, M., Whole-body magnetic resonance for staging and response assessment of lymphoma in a pregnant woman treated with antenatal chemotherapy (2016) BJR Case Rep, 3 (1). , https://doi.org/10.1259/bjrcr.20150293; Chen, Y., Zhong, J., Wu, H., Chen, N., The clinical application of whole-body diffusionweighted imaging in the early assessment of chemoterapeutic effects in lymphoma: the initial experience (2012) Magn Reson Imaging, 30 (2), pp. 165-170. , https://doi.org/10.1016/j.mri.2011.09.019; Cheson, B.D., Fisher, R.I., Barrington, S.F., Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification (2014) J Clin Oncol, 32 (27), pp. 3059-3068. , https://doi.org/10.1200/JCO.2013.54.8800; Horwitz, S.M., Zelenetz, A.D., Gordon, L.I., NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016 (2016) J Natl Compr Canc Netw, 14 (9), pp. 1067-1079; Chien, S.H., Liu, C.J., Hu, Y.W., Frequency of surveillance computed tomography in non-Hodgkin lymphoma and the risk of secondary primary malignancies: A nationwide population-based study (2015) Int J Cancer, 137 (3), pp. 658-665. , https://doi.org/10.1002/ijc.29433; Huang, B., Law, M.W., Khong, P.L., Whole-body PET/CT scanning: estimation of radiation dose and cancer risk (2009) Radiology, 251 (1), pp. 166-174. , https://doi.org/10.1148/radiol.2511081300; Lauenstein, T.C., Semelka, R.C., Emerging techniques: whole-body screening and staging with MRI (2006) J Magn Reson Imaging, 24 (3), pp. 489-498. , https://doi.org/10.1002/jmri.20666; Kwee, T.C., Kwee, R.M., Nievelstein, R.A., Imaging in staging of malignant lymphoma: a systematic review (2008) Blood, 111 (2), pp. 504-516. , https://doi.org/10.1182/blood-2007-07-101899; Galia, M., Albano, D., Narese, D., Whole-body MRI in patients with lymphoma: collateral findings (2016) Radiol Med, 121 (10), pp. 793-800. , https://doi.org/10.1007/s11547-016-0658-x; Chianca, V., Albano, D., Messina, C., Diffusion tensor imaging in the musculoskeletal and peripheral nerve systems: from experimental to clinical applications (2017) Eur Radiol Exp, 1 (1), p. 12. , https://doi.org/10.1186/s41747-017-0018-1; Kwee, T.C., Basu, S., Torigian, D.A., Nievelstein, R.A., Alavi, A., Evolving Importance of Diffusion-Weighted Magnetic Resonance Imaging in Lymphoma (2012) PET Clin, 7 (1), pp. 73-82. , https://doi.org/10.1016/j.cpet.2011.11.001; Morone, M., Bali, M.A., Tunariu, N., Whole-Body MRI: Current Applications in Oncology (2017) AJR Am J Roentgenol, 209 (6), pp. W336-W349. , https://doi.org/10.2214/AJR.17.17984; Stecco, A., Buemi, F., Iannessi, A., Carriero, A., Gallamini, A., Current concepts in tumor imaging with whole-body MRI with diffusion imaging (WB-MRI-DWI) in multiple myeloma and lymphoma (2018) Leuk Lymphoma, 12 (11), pp. 1-11. , https://doi.org/10.1080/10428194.2018.1434881; Wang, D., Huo, Y., Chen, S., Whole-body MRI versus (18)F-FDG PET/CT for pretherapeutic assessment and staging of lymphoma: a meta-analysis (2018) Onco Targets Ther, 11, pp. 3597-3608. , https://doi.org/10.2147/OTT.S148189; Azzedine, B., Kahina, M.B., Dimitri, P., Christophe, P., Alain, D., Claude, M., Whole-body diffusion-weighted MRI for staging lymphoma at 3.0 T: comparative study with MR imaging at 1.5 T (2015) Clin Imaging, 39 (1), pp. 104-109. , https://doi.org/10.1016/j.clinimag.2014.06.017; Moskowitz, C.H., Interim PET-CT in the management of diffuse large B-cell lymphoma (2012) Hematology Am Soc Hematol Educ Program, 2012, pp. 397-401. , https://doi.org/10.1182/asheducation-2012.1.397; Albano, D., Patti, C., Lagalla, R., Midiri, M., Galia, M., Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma (2017) J Magn Reson Imaging, 45 (4), pp. 1082-1089. , https://doi.org/10.1002/jmri.25439; Rademaker, J., Ryan, D., Matasar, M., Portlock, C., Whole-body diffusion-weighted MR imaging in lymphoma surveillance (2017) Hematol Oncol, 35 (S2), pp. 304-305. , https://doi.org/10.1002/hon.2439_39, 14th International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland); Albano, D., La Grutta, L., Grassedonio, E., Pitfalls in whole body MRI with diffusion weighted imaging performed on patients with lymphoma: What radiologists should know (2016) Magn Reson Imaging, 34 (7), pp. 922-931. , https://doi.org/10.1016/j.mri.2016.04.023; Mayerhoefer, M.E., Karanikas, G., Kletter, K., Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients (2014) Clin Cancer Res, 20 (11), pp. 2984-2993. , https://doi.org/10.1158/1078-0432.CCR-13-3355; Chavhan, G.B., Babyn, P.S., Whole-body MR imaging in children: principles, technique, current applications, and future directions (2011) Radiographics, 31 (6), pp. 1757-1772. , https://doi.org/10.1148/rg.316115523; Punwani, S., Cheung, K.K., Skipper, N., Dynamic contrast-enhanced MRI improves accuracy for detecting focal splenic involvement in children and adolescents with Hodgkin disease (2013) Pediatr Radiol, 43 (8), pp. 941-949. , https://doi.org/10.1007/s00247-012-2616-7; Doniselli, F.M., Albano, D., Chianca, V., Cimmino, M.A., Sconfienza, L.M., Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: what rheumatologists should know (2017) Clin Rheumatol, 36 (5), pp. 977-980. , https://doi.org/10.1007/s10067-017-3604-y; Savarino, E., Chianca, V., Bodini, G., Gadolinium accumulation after contrast-enhanced magnetic resonance imaging: Which implications in patients with Crohn's disease? (2017) Dig Liver Dis, 49 (7), pp. 728-730. , https://doi.org/10.1016/j.dld.2017.04.010; Plathow, C., Walz, M., Lichy, M.P., Cost considerations for whole-body MRI and PET/CT as part of oncologic staging (2008) Radiologe, 48 (4), pp. 384-396. , https://doi.org/10.1007/s00117-007-1547-z; Albano, D., Agnello, F., Patti, C., Whole-body magnetic resonance imaging and FDG-PET/CT for lymphoma staging: Assessment of patient experience (2017) Egypt J Radiol Nucl Med, 48 (4), pp. 1043-1047. , https://doi.org/10.1016/j.ejrnm.2017.06.002; Adams, H.J., Kwee, T.C., Vermoolen, M.A., Ludwig, I., Bierings, M.B., Nievelestein, R.A., Whole-body MRI vs. CT for staging lymphoma: patient experience (2014) Eur J Radiol, 83 (1), pp. 163-166. , https://doi.org/10.1016/j.ejrad.2013.10.008; Shanbhag, S., Ambinder, R.F., Hodgkin lymphoma: A review and update on recent progress (2017) CA Cancer J Clin, 68 (2), pp. 116-132. , https://doi.org/10.3322/caac.21438; Gallamini, A., Hutchings, M., Rigacci, L., Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study (2007) J Clin Oncol, 25 (24), pp. 3746-3752; Gallamini, A., Tarella, C., Viviani, S., Early Chemotherapy Intensification With Escalated BEACOPP in Patients With Advanced-Stage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial (2018) J Clin Oncol, 36 (5), pp. 454-462. , https://doi.org/10.1200/JCO.2017.75.2543; Littooij, A.S., Kwee, T.C., Barber, I., Whole-body MRI for initial staging of paediatric lymphoma: prospective comparison to an FDG-PET/CT-based reference standard (2014) Eur Radiol, 24 (5), pp. 1153-1165. , https://doi.org/10.1007/s00330-014-3114-0; Albano, D., Patti, C., La Grutta, L., Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas (2016) Eur J Radiol, 85 (2), pp. 313-318. , https://doi.org/10.1016/j.ejrad.2015.12.006; Albano, D., Patti, C., Matranga, D., Lagalla, R., Midiri, M., Galia, M., Whole-body diffusion-weighted MR and FDG-PET/CT in Hodgkin Lymphoma: Predictive role before treatment and early assessment after two courses of ABVD (2018) Eur J Radiol, 103, pp. 90-98. , https://doi.org/10.1016/j.ejrad.2018.04.014; Horger, M., Claussen, C., Kramer, U., Fenchel, M., Lichy, M., Kaufmann, S., Very early indicators of response to systemic therapy in lymphoma patients based on alterations in water diffusivity—a preliminary experience in 20 patients undergoing whole-body diffusion-weighted imaging (2014) Eur J Radiol, 83 (9), pp. 1655-1664. , https://doi.org/10.1016/j.ejrad.2014.05.027; Latifoltojar, A., Punwani, S., Lopes, A., Whole-body MRI for staging and interim response monitoring in paediatric and adolescent Hodgkin's lymphoma: a comparison with multi-modality reference standard including (18)F-FDG-PET-CT (2019) Eur Radiol, 29 (1), pp. 202-212. , https://doi.org/10.1007/s00330-018-5445-8; Rahmouni, A., Divine, M., Kriaa, S., Haioun, C., Anglade, M.C., Kobelter, H., Lymphoma: imaging in the evaluation of residual masses (2002) Cancer Imaging, 2 (2), pp. 93-95. , https://doi.org/10.1102/1470-7330.2002.0008; Albano, D., Patti, C., La Grutta, L., Osteonecrosis detected by whole body magnetic resonance in patients with Hodgkin Lymphoma treated by BEACOPP (2017) Eur Radiol, 27 (5), pp. 2129-2136. , https://doi.org/10.1007/s00330-016-4535-8; Littooij, A.S., Kwee, T.C., Enríquez, G., Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma (2017) Br J Haematol, 176 (4), pp. 637-642. , https://doi.org/10.1111/bjh.14452; Albano, D., Patti, C., Midiri, M., Galia, M., Osteonecrosis in Hodgkin lymphoma treated by BEACOPP (2018) Intern Med J, 48 (6), pp. 747-748. , https://doi.org/10.1111/imj.13813; Albano, D., Patti, C., Sconfienza, L.M., Galia, M., Whole-body MRI in the early detection of multifocal osteonecrosis (2017) Br J Radiol, 90 (1077). , https://doi.org/10.1259/bjr.20170280; Sehn, L.H., Introduction to a clinical review series on aggressive B-cell lymphoma (2015) Blood, 125 (1), pp. 1-2. , https://doi.org/10.1182/blood-2014-09-594580; Shah, H.J., Keraliya, A.R., Jagannathan, J.P., Tirumani, S.H., Lele, V.R., DiPiro, P.J., Diffuse Large B-Cell Lymphoma in the Era of Precision Oncology: How Imaging Is Helpful (2017) Korean J Radiol, 18 (1), pp. 54-70. , https://doi.org/10.3348/kjr.2017.18.1.54; Ceriani, L., Martelli, M., Conconi, A., Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study (2017) Br J Haematol, 178 (4), pp. 588-591. , https://doi.org/10.1111/bjh.14728; Johnson, S.A., Kumar, A., Matasar, M.J., Schöder, H., Rademaker, J., Imaging for Staging and Response Assessment in Lymphoma (2015) Radiology, 276 (2), pp. 323-338. , https://doi.org/10.1148/radiol.2015142088; Dreyling, M., Ferrero, S., Hermine, O., How to manage mantle cell lymphoma (2014) Leukemia, 28 (11), pp. 2117-2130. , https://doi.org/10.1038/leu.2014.171; Tsukamoto, N., Kojima, M., Hasegawa, M., The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification (2007) Cancer, 110 (3), pp. 652-659. , https://doi.org/10.1002/cncr.22807; Kwee, T.C., Vermoolen, M.A., Akkerman, E.A., Whole-body MRI, including diffusion-weighted imaging, for staging lymphoma: comparison with CT in a prospective multicenter study (2014) J Magn Reson Imaging, 40 (1), pp. 26-36. , https://doi.org/10.1002/jmri.24356; Brennan, D.D., Gleeson, T., Coate, L.E., Cronin, C., Carney, D., Eustace, S.J., A comparison of whole- body MRI and CT for the staging of lymphoma (2005) AJR Am J Roentgenol, 185 (3), pp. 711-716. , https://doi.org/10.2214/ajr.185.3.01850711; Lin, C., Luciani, A., Itti, E., Whole-body diffusion-weighted magnetic resonance imaging with apparent diffusion coefficient mapping for staging patients with diffuse large B-cell lymphoma (2010) Eur Radiol, 20 (8), pp. 2027-2038. , https://doi.org/10.1007/s00330-010-1758-y; Abdulqadhr, G., Molin, D., Aström, G., Whole-body diffusion-weighted imaging compared with FDG-PET/CT in staging of lymphoma patients (2011) Acta Radiol, 52 (2), pp. 173-180. , https://doi.org/10.1258/ar.2010.100246; Adams, H.J.A., Kwee, T.C., Vermoolen, M.A., Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET (2013) Eur Radiol, 23 (8), pp. 2271-2278. , https://doi.org/10.1007/s00330-013-2835-9; Haddy, T.B., Parker, R.I., Magrath, I.T., Bone marrow involvement in young patients with non-Hodgkin's lymphoma: the importance of multiple bone marrow samples for accurate staging (1989) Med Pediatr Oncol, 17 (5), pp. 418-423; Adams, H.J., Kwee, T.C., Lokhorst, H.M., Potential prognostic implications of whole-body bone marrow MRI in diffuse large B-cell lymphoma patients with a negative blind bone marrow biopsy (2014) J Magn Reson Imaging, 39 (6), pp. 1394-1400. , https://doi.org/10.1002/jmri.24318; Sun, M., Cheng, J., Zhang, Y., Wang, F., Meng, Y., Fu, X., Application value of diffusion weighted whole body imaging with background body signal suppression in monitoring the response to treatment of bone marrow involvement in lymphoma (2016) J Magn Reson Imaging, 44 (6), pp. 1522-1529. , https://doi.org/10.1002/jmri.25300; Lin, C., Itti, E., Luciani, A., Whole-body diffusion-weighted imaging with apparent diffusion coefficient mapping for treatment response assessment in patients with diffuse large B-cell lymphoma: pilot study (2011) Invest Radiol, 46 (5), pp. 341-349. , https://doi.org/10.1097/RLI.0b013e3182087b03; De Paepe, K., Bevernage, C., De Keyzer, F., Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study (2013) Cancer Imaging, 13 (1), pp. 53-62. , https://doi.org/10.1102/1470-7330.2013.0006; Mayerhoefer, M.E., Karanikas, G., Kletter, K., Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients (2015) Clin Cancer Res, 21 (11), pp. 2506-2513. , https://doi.org/10.1158/1078-0432.CCR-14-2454; Wu, X., Korkola, P., Pertovaara, H., Eskola, H., Järvenpää, R., Kellokumpu-Lehtinen, P.L., No correlation between glucose metabolism and apparent diffusion coefficient in diffuse large B-cell lymphoma: a PET/CT and DW-MRI study (2011) Eur J Radiol, 79 (2). , https://doi.org/10.1016/j.ejrad.2011.04.062; Sun, M., Cheng, J., Zhang, Y., Application of DWIBS in malignant lymphoma: correlation between ADC values and Ki-67 index (2018) Eur Radiol, 28 (4), pp. 1701-1708. , https://doi.org/10.1007/s00330-017-5135-y; Lunning, M.A., Vose, J.M., Management of indolent lymphoma: where are we now and where are we going (2012) Blood Rev, 26 (6), pp. 279-288. , https://doi.org/10.1016/j.blre.2012.09.004; Armitage, J.O., Longo, D.L., Is watch and wait still acceptable for patients with low-grade follicular lymphoma? (2016) Blood, 127 (23), pp. 2804-2808. , https://doi.org/10.1182/blood-2015-11-632745; Sorigue, M., Sancho, J.M., Ribera, J.M., Open questions in watchful waiting for follicular lymphoma (2017) Br J Haematol, 179 (4), pp. 679-681. , https://doi.org/10.1111/bjh.14246; Carrillo-Cruz, E., Marín-Oyaga, V.A., de la Cruz Vicente, F., Role of 18F-FDG-PET/CT in the management of marginal zone B cell lymphoma (2015) Hematol Oncol, 33 (4), pp. 151-158. , https://doi.org/10.1002/hon.2181; Albano, D., Bosio, G., Camoni, L., Prognostic role of baseline (18) F-FDG PET/CT parameters in MALT lymphoma (2018) Hematol Oncol, 37 (1), pp. 39-46. , https://doi.org/10.1002/hon.2563; Balbo-Mussetto, A., Cirillo, S., Bruna, R., Whole-body MRI with diffusion-weighted imaging: a valuable alternative to contrast-enhanced CT for initial staging of aggressive lymphoma (2016) Clin Radiol, 71 (3), pp. 271-279. , https://doi.org/10.1016/j.crad.2015.11.018; Littooij, A.S., Kwee, T.C., de Keizer, B., Whole-body MRI-DWI for assessment of residual disease after completion of therapy in lymphoma: A prospective multicenter study (2015) J Magn Reson Imaging, 42 (6), pp. 1646-1655. , https://doi.org/10.1002/jmri.24938; Stecco, A., Buemi, F., Quagliozzi, M., Staging of Primary Abdominal Lymphomas: Comparison of Whole-Body MRI with Diffusion-Weighted Imaging and (18)F-FDG-PET/CT (2015) Gastroenterol Res Pract, 2015. , https://doi.org/10.1155/2015/104794; Mayerhoefer, M.E., Karanikas, G., Kletter, K., Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?: A Preliminary Study in 15 Patients (2016) Clin Nucl Med, 41 (11), pp. 837-843. , https://doi.org/10.1097/RLU.0000000000001395; Mosavi, F., Wassberg, C., Selling, J., Molin, D., Ahlström, H., Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes (2015) Clin Radiol, 70 (11), pp. 1229-1236. , https://doi.org/10.1016/j.crad.2015.06.087; Adams, H.J., Kwee, T.C., Vermoolen, M.A., Whole-body MRI for the detection of bone marrow involvement in lymphoma: prospective study in 116 patients and comparison with FDG-PET (2013) Eur Radiol, 23 (8), pp. 2271-2278. , https://doi.org/10.1007/s00330-013-2835-9; Luminari, S., Biasoli, I., Arcaini, L., The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi (2013) Ann Oncol, 24 (8), pp. 2108-2112. , https://doi.org/10.1093/annonc/mdt137; Smith, S.D., Redman, M., Dunleavy, K., FDG PET-CT in follicular lymphoma: a case-based evidence review (2015) Blood, 125 (7), pp. 1078-1082. , https://doi.org/10.1182/blood-2014-11-537522; Lossos, I.S., Gascoyne, R.D., Transformation of follicular lymphoma (2011) Best Pract Res Clin Haematol, 24 (2), pp. 147-163. , https://doi.org/10.1016/j.beha.2011.02.006; Punwani, S., Taylor, S.A., Saad, Z.Z., Diffusion-weighted MRI of lymphoma: prognostic utility and implications for PET/MRI? (2013) Eur J Nucl Med Mol Imaging, 40 (3), pp. 373-385. , https://doi.org/10.1007/s00259-012-2293-7; Mayerhoefer, M.E., Archibald, S.J., Messiou, C., Staudenherz, A., Berzaczy, D., Schöder, H., MRI and PET/MRI in hematologic malignancies (2019) J Magn Reson Imaging, n/a (n/a), p. n/a. , https://doi.org/10.1002/jmri.26848; Giraudo, C., Raderer, M., Karanikas, G., 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging (2016) Invest Radiol, 51 (3), pp. 163-169. , https://doi.org/10.1097/RLI.0000000000000218; Afaq, A., Fraioli, F., Sidhu, H., Comparison of PET/MRI With PET/CT in the Evaluation of Disease Status in Lymphoma (2017) Clin Nucl Med, 42 (1). , https://doi.org/10.1097/RLU.0000000000001344; Herrmann, K., Queiroz, M., Huellner, M.W., Diagnostic performance of FDG-PET/MRI and WB-DW-MRI in the evaluation of lymphoma: a prospective comparison to standard FDG-PET/CT (2015) BMC Cancer, 15 (1), p. 1002. , https://doi.org/10.1186/s12885-015-2009-z; Parmar, C., Leijenaar, R.T., Grossmann, P., Radiomic feature clusters and prognostic signatures specific for lung and head & neck cancer (2015) Sci Rep, 5 (1). , https://doi.org/10.1038/srep11044; Burrell, R.A., McGranahan, N., Bartek, J., Swanton, C., The causes and consequences of genetic heterogeneity in cancer evolution (2013) Nature, 501 (7467), pp. 338-345. , https://doi.org/10.1038/nature12625; Ceriani, L., Milan, L., Martelli, M., Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma (2018) Blood, 132 (2), pp. 179-186. , https://doi.org/10.1182/blood-2018-01-826958; De Paepe, K.N., De Keyzer, F., Wolter, P., Improving lymph node characterization in staging malignant lymphoma using first-order ADC texture analysis from whole-body diffusion-weighted MRI (2018) J Magn Reson Imaging, 48 (4), pp. 897-906. , https://doi.org/10.1002/jmri.26034; Wu, X., Sikiö, M., Pertovaara, H., Differentiation of Diffuse Large B-cell Lymphoma From Follicular Lymphoma Using Texture Analysis on Conventional MR Images at 3.0 Tesla (2016) Acad Radiol, 23 (6), pp. 696-703. , https://doi.org/10.1016/j.acra.2016.01.012; Galia, M., Albano, D., Tarella, C., Whole body magnetic resonance in indolent lymphomas under watchful waiting: The time is now (2018) Eur Radiol, 28 (3), pp. 1187-1193. , https://doi.org/10.1007/s00330-017-5071-x
PY - 2020
Y1 - 2020
N2 - The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imaging procedures. WB-MRI seems a less histology-dependent functional imaging test than 18F-fluorodeoxyglucose-positron emission tomography/CT (18F-FDG-PET/CT). In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB-MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB-MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas. © 2019 John Wiley & Sons, Ltd.
AB - The improvements in magnetic resonance imaging (MRI) technology and the concern related to the increased cancer risk in patients with lymphoma, also due to radiation exposure associated with imaging examinations, have led to the introduction of whole-body MRI (WB-MRI) as a radiation-free alternative to standard imaging procedures. WB-MRI seems a less histology-dependent functional imaging test than 18F-fluorodeoxyglucose-positron emission tomography/CT (18F-FDG-PET/CT). In patients with FDG-avid lymphomas, such as diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL), 18F-FDG-PET/CT remains the imaging reference standard for staging, with WB-MRI potentially being a complementary modality that could replace CT, especially in young patients. On the other hand, WB-MRI is a valuable imaging procedure for lymphoma surveillance and in lymphomas with variable/low FDG avidity and nonfollicular indolent lymphomas. The aim of this paper is to discuss the current state of the art of WB-MRI in lymphoma by evaluating its diagnostic performance in different lymphoma subtypes: Hodgkin, aggressive, and indolent lymphomas. © 2019 John Wiley & Sons, Ltd.
KW - lymphoma
KW - magnetic resonance imaging
KW - positron emission tomography
KW - whole-body imaging
KW - contrast medium
KW - fluorodeoxyglucose f 18
KW - gadolinium
KW - radiopharmaceutical agent
KW - rituximab
KW - anaplastic large cell lymphoma
KW - apparent diffusion coefficient
KW - B cell lymphoma
KW - cancer staging
KW - diffuse large B cell lymphoma
KW - diffusion weighted imaging
KW - follicular lymphoma
KW - gastrointestinal lymphoma
KW - Hodgkin disease
KW - human
KW - intermethod comparison
KW - mantle cell lymphoma
KW - peripheral T cell lymphoma
KW - positron emission tomography-computed tomography
KW - predictive value
KW - priority journal
KW - radiation exposure
KW - Review
KW - T cell lymphoma
KW - treatment response
KW - whole body MRI
KW - animal
KW - nuclear magnetic resonance imaging
KW - procedures
KW - whole body imaging
KW - Animals
KW - Humans
KW - Lymphoma
KW - Magnetic Resonance Imaging
KW - Neoplasm Staging
KW - Whole Body Imaging
U2 - 10.1002/hon.2676
DO - 10.1002/hon.2676
M3 - Article
VL - 38
SP - 12
EP - 21
JO - Hematol. Oncol.
JF - Hematol. Oncol.
SN - 0278-0232
IS - 1
ER -